AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03698318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tested product n°3
Description: 2 capsules (6.8% of gingerol/shogaol in 424.3 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
Study NCT03698318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tested product n°4
Description: 1 capsule (27% of gingerol/shogaol in 104.9 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
Study NCT03698318 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tested product n°5
Description: 6 capsules (1.6% of gingerol/shogaol in 1806.25 mg) to consume one time for each subject, at one experimental session (random assignment), with 250 mL of water (consumption at T0 time-point of the kinetic)
Study NCT00717873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airway clearance Device
Description: Provided by the Vest Airway clearance system
Study NCT02024698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A
Description: contact lens
Study NCT02024698 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: etafilcon A
Description: contact lens
Study NCT02896855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study NCT02896855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel (75-mg/m\^2) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study NCT02896855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study NCT02896855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo matched to pertuzumab was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study NCT02896855 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) was administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
Study NCT02001428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dihydroartemisinin-piperaquine
Description: Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
Study NCT03437460 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen 600 mg
Description: The investigators administer one single 600 mg dose of ibuprofen immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
Study NCT03437460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prenatal vitamins
Description: The investigators administer one single prenatal multivitamin immediately before lunch. Participants are then asked to complete the cold pressor task, flower stringing sessions, and cognitive tasks.
Study NCT00370396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Synflorix
Description: 1 dose injected IM in the right thigh or deltoid.
Study NCT00370396 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Prevenar
Description: 1 dose injected IM in the right thigh or deltoid.
Study NCT00370396 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Infanrix hexa
Description: 1 dose injected IM in the right thigh or deltoid.
Study NCT00370396 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infanrix hexa
Description: 1 dose injected IM in the right thigh or deltoid.
Study NCT00895583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
Study NCT00895583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
Study NCT00895583 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
Study NCT06521034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FHND-9041
Description: In Phase I, using a 3+3 design, dose escalation and expansion studies were conducted at doses of 40, 80, 120 and 180 mg/day. At least 3 patients were enrolled in each dose arm, and no dose-limiting toxicities were observed. With a plateau observed at 120 mg/day, the 80 mg/d and 120mg/d groups were selected for dose expansion. The 80mg/d queue has expanded by 36 patients, and the 120mg/d queue has expanded by 39 patients. In Phase Ⅱ, after comprehensive analysis and consultation, at least 30 patients were enrolled according to the inclusion and exclusion criteria. 37 patients with locally advanced or metastatic EGFR-mutated NSCLC receiving first-line treatment were enrolled.
Study NCT00947518 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine
Description: Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
Study NCT00947518 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Cleansing the skin (except the face)with baby wipes containing normal saline
Study NCT02662608 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brontictuzumab
Description: 1.5 mg/Kg intravenously every three weeks.
Study NCT01584726 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Magnesium Sulfate
Description: single dose of magnesium sulfate nebulization
Study NCT02481479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
Study NCT02481479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saxagliptin
Description: Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
Study NCT02481479 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: saxagliptin
Description: Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
Study NCT02545010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.~Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.~Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician.
Study NCT02545010 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: LDWART (Low Dose Whole Abdominal Radiation Therapy)
Description: LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.~LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator.
Study NCT00216944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation for respiratory care in preterm infants
Description: Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
Study NCT00216944 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation for respiratory care in preterm infants
Description: Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (\< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
Study NCT05102045 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: TMS is a non-invasive application that induces changes in neuronal polarization and activity by causing the induction of weak electric currents in a rapidly changing magnetic field. Repetitive TMS (rTMS) refers to the application of regular TMS pulses at fixed intervals.
Study NCT05102045 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Brisk exercise that promotes the circulation of oxygen through the blood and is associated with an increased rate of breathing.
Study NCT05102045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylcholinesterase Inhibitors
Description: Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
Study NCT05102045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetylcholinesterase Inhibitors
Description: Donepezil, Rivastigmine, Galantamine were given in combination for Alzheimer's disease.
Study NCT05102045 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine were given for Alzheimer's disease. .
Study NCT05102045 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Memantine
Description: Memantine were given for Alzheimer's disease. .
Study NCT03000868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cold endoscopic mucosal resection
Description: Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
Study NCT03000868 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hot endoscopic mucosal resection
Description: Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (\<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
Study NCT01289431 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: administered daily to each eye for 2 weeks following allergen challenge using a CAC model
Study NCT01289431 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: administered daily to each eye for 2 weeks following allergen challenge using a CAC model
Study NCT01906099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: nutritional intervention
Study NCT01906099 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: life style modification
Study NCT03167814 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet group
Description: In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
Study NCT05842577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy)
Description: The motor exercises were performed using inertial sensors for the acquisition and processing of the movement performed by the patient. The patient was trained to perform these exercises using visual and auditory feedback in a serious game environment. The exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc.). The therapists involved in the study customized the protocol of exercises in TR mode according to the characteristics and needs of the subject.
Study NCT05842577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: At-home conventional rehabilitation
Description: The CG rehabilitation was an active comparator treatment and consisted of a written home-based self-administered booklet with conventional motor activities tailored for each subject. The motor activities were chosen and adapted from a specialized manual. The motor exercises were aimed at the rehabilitation of balance and at the improvement of motor performance in lower limbs (e.g., maintaining balance on one leg, marching in place, standing on tiptoe, squatting, etc).
Study NCT03827499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent physical exercise program
Description: Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
Study NCT02393534 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Visit
Description: Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
Study NCT04364724 — intervention group
Intervention type: OTHER
Intervention: CT-based finite element analysis
Description: CTFEA is a computerized analysis of CT-scans which simulates stress testing of finite element models of various bones (in this study - femurs and vertebrae).~No intervention is planned - the study is observational. CT scans are performed for follow-up as an accepted standard of care. Secondary use of CT scans for CTFEA is in addition to the standard of care.~In a case when CTFEA analysis detects a high risk of pathologic fracture, the treating hematologist will be informed and will refer the patient for evaluation at the National Unit of Orthopedic Oncology.
Study NCT02693678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage
Study NCT02693678 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIathermy
Study NCT02693678 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham diathermy
Study NCT03700528 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT)
Description: The process will involve, two, brief, one-to-one contact sessions, one at the beginning and one at the end of the intervention, in a way that is convenient for participants, including Skype, phone, or face to face in person. Following the first one-to-one session there will be eight short online sessions, about 20-30 minutes each. Participants will also be asked to complete some tasks between the sessions, in particular to record their progress briefly and any changes at their medication (i.e. type of drug, dose) in a diary weekly so that they can keep track of your developing skills.
Study NCT03806322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Pneumatic Compression
Description: The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and intermittent pneumatic compression.
Study NCT03806322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold-pack
Description: The group received ultrasound, transcutaneous electrical nerve stimulation, electrical stimulation, exercise, and cold packs.
Study NCT01331083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: PX-866: 8mg orally taken daily
Study NCT00630682 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextroamphetamine
Description: 1 week placebo and 8 weeks 60mg d-AMP QD.
Study NCT00630682 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 9 weeks of placebo 60mg capsules QD.
Study NCT02557594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viread 300mg
Description: single dose administration after 10hr fasting
Study NCT02557594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DA-2802 319mg
Description: single dose administration after 10hr fasting
Study NCT02609282 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hourly prompts to stand delivered by Microsoft Outlook
Study NCT01987700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FLEX-HD
Study NCT01987700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Strattice
Study NCT04528628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Description: Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
Study NCT04528628 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
Study NCT03827499 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Multicomponent physical exercise program
Description: Intervention groups including exercise (Ex-HMB and Ex-Plac) will complete an individualized multicomponent training program, five days a week during 24 weeks.
Study NCT04528628 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors) Combined with Magnetic Stimulations
Description: Drug therapies are the same as the SSRIs/SNRIs monotherapy group. Patients will randomly receive one kind of magnetic stimulations including repetitive transcranial magnetic stimulation (rTMS), continuous theta burst stimulation(cTBS) and intermittent theta burst stimulation (iTBS) at a ratio of 1:1:1.
Study NCT02767622 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Study NCT04566783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Psychological/psychiatric examination
Description: Thorough diagnostic and (neuro)psychological assessment using standardized clinical interviews (e.g. MINI, SOMS) as well as questionnaires assessing sexual function (e.g. SIS/SES), depression and anxiety (HADS), childhood trauma (CTQ) and life quality (WHOQOL-BREF). In a semi-structured interview sociodemographic data, drug history and sexual characteristics are captured.
Study NCT04566783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neurological examination
Description: Standardized clinical neurological examination as well as neurophysiological measurements (Pudenus-SEP, ENoG, clinical EEG).
Study NCT04566783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Gynecological/urological examination
Description: Standard clinical investigation including ultrasound of the genital organs will be conducted to look for any somatic pathology (e.g. varices, tumors).
Study NCT04566783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory assessment
Description: Blood sample will be analyzed to evaluate (epi-)genetic markers of increased central excitability or decreased inhibition including specific parameters of the serotonin-, dopamine- and endocannabinoid system.
Study NCT04566783 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Structural and Functional Magnetic Resonance Imaging
Description: 1. Structural MRI of the pelvis is conducted to rule out any anatomical pathologies underlying PGAD (e.g. varices).~2. Structural MRI of the lumbosacral spinal cord to look for any pathologies on the spinal level, especially spinal level S2-4 (e.g. Tarlov cysts).~3. High-resolution structural MRI (T1) including brain stem will be applied to all participants in order to explore alterations in gray matter volume or density.~4. Structural differences in white matter will be assessed using a high-resolution DTI sequence. In addition to standard voxel-wise comparison of DTI derived parameters for white matter microstructural integrity, a tractography-based analysis will test for alterations in structural connectivity.~5. Resting-state functional MRI including brain stem scans will evaluate abnormal brain circuitry at rest (resting-state functional connectivity, RSFC).~6. Functional MRI to assess brain response towards sexual cue reactivity.
Study NCT00686803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PL3994
Description: Study drug
Study NCT00686803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03872700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal fentanyl
Description: Fentanyl Citrate
Study NCT03872700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sterile Water Up to 5Cc
Study NCT00389311 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normosol-R